• PRIYANKA VENUNGOPAL Department of Clinical Research, Hindu Mission Hospital, Chennai, Tamil Nadu, India.
  • KARTHIKEYAN BALAKRISHNAN Department of Cardiology, Hindu Mission Hospital, Chennai, Tamil Nadu, India.
  • DAMAL KANDADAI SRIRAM Department of Diabetology and Endocrinology, Hindu Mission Hospital, Chennai, Tamil Nadu, India.
  • MELVIN GEORGE Department of Clinical Research, Hindu Mission Hospital, Chennai, Tamil Nadu, India.



RNAi therapeutics, inclisiran, lipoproteins, statin intolerance, cardiovascular diseases


Elevated levels of low density lipoprotein (LCL) – cholesterols are an established risk factor for the development and progression of cardiovascular diseases, particularly atherosclerosis. Statins are the first-line treatment for dyslipidemia which helps in lowering lipid levels (bad cholesterol). Although statin therapy is a conventional and gold-standard method, some patients who have high cardiovascular risk are either intolerant to statins or have persistently elevated LDL levels despite receiving highest dose of statin. Therefore, for such patients, proprotein convertase subtilisin/ kexin Type 9 (PCSK9) inhibitor drugs are recommended. This review highlights the importance of PCSK9 inhibitors, focusing mainly on the recently approved (Food and Drug Administration) first-in-class small interfering RNA therapeutic drug called inclisiran (Leqvio) developed by Novartis. The article also summarizes the safety and efficacy of inclisiran based on the ORION clinical trials, benefits, and cost-effectiveness over other previously approved PCSK9 inhibitor drugs.


Download data is not yet available.


The Top 10 Causes of Death. 2022. Available from: https://www.who. int/news-room/fact-sheets/detail/the-top-10-causes-of-death [Last accessed on 2022 May 19].

Cardiovascular Diseases (CVDs). 2022. Available from: https://www. [Last accessed on 2022 May 19].

Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;63:2889-934.

Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2011;32:1769-818. doi: 10.1093/eurheartj/ehr158

Ference BA, Mahajan N. The role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep 2013;15:312. doi: 10.1007/s11883-013-0312-1, PMID 23423521

Page MM, Watts GF. Emerging PCSK9 inhibitors for treating dyslipidaemia: Buttressing the gaps in coronary prevention. Expert Opin Emerg Drugs 2015;20:299-312. doi: 10.1517/14728214.2015.1035709, PMID 25861882

Feingold KR, Grunfeld C, Anawalt B, Boyce A, de Herder WW, Dhatariya K, et al. Introduction to lipids and lipoproteins. In: Endotext. South Dartmouth (MA):, Inc.; 2000.

Sabatine MS. PCSK9 inhibitors: Clinical evidence and implementation. Nat Rev Cardiol 2019;16:155-65. doi: 10.1038/s41569-018-0107-8, PMID 30420622

Stancu C, Sima A. Statins: Mechanism of action and effects. J Cell Mol Med 2001;5:378-87. doi: 10.1111/j.1582-4934.2001.tb00172.x, PMID 12067471

Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: The fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf 2014;13:1227-39. doi: 10.1517/14740338.2014.937422, PMID 25017015

Leren TP. Sorting an LDL receptor with bound PCSK9 to intracellular degradation. Atherosclerosis 2014;237:76-81. doi: 10.1016/j. atherosclerosis.2014.08.038, PMID 25222343

Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin/kexin Type 9 inhibition: A new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 2015;132:1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080, PMID 26503748

Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb 2017;24:895-907. doi: 10.5551/jat.RV17012, PMID 28804094

Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic- Kalimanovska V. Obesity and dyslipidemia. Metabolism 2019;92:71-81. doi: 10.1016/j.metabol.2018.11.005, PMID 30447223

Fisher TS, Lo Surdo PL, Pandit S, Mattu M, Santoro JC, Wisniewski D, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9- dependent LDL receptor regulation. J Biol Chem 2007;282:20502-12. doi: 10.1074/jbc.M701634200, PMID 17493938

Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif 2018;46:144-52. doi: 10.1159/000488816, PMID 29705798

Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017;9:76-91. doi: 10.4330/ wjc.v9.i2.76, PMID 28289523

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: State of the art. Signal Transduct Target Ther 2020;5:101.

Novartis Receives EU Approval for Leqvio® (inclisiran), A First-in- Class siRNA to Lower Cholesterol with Two Doses a Year. Basel: Novartis; 2022 Available from: [Last accessed on 2022 May 19].

Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: The ORION clinical development program. Future Cardiol 2018;14:433-42. doi: 10.2217/ fca-2018-0067, PMID 30375244

ALN PCSsc-New Drug Approvals. 2022. Available from: https://www. [Last accessed on 2022 May 19].

2022. Available from: Resource/Download/6dcafc22-cdc3-42dd-913c-a8b048d17c40 [Last accessed on 2022 May 19].

Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020;382:1520-30. doi: 10.1056/ NEJMoa1913805, PMID 32197277

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al.Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-19. doi: 10.1056/NEJMoa1912387, PMID 32187462

2022. Available from: [Last accessed on 2022 May 19].

Lamb YN. Inclisiran: First approval. Drugs 2021;81:389-95. doi: 10.1007/s40265-021-01473-6, PMID 33620677

Kimzey AL, Piche MS, Wood M, Weir AB, Lansita J. Immunophenotyping in drug development. Compr Toxicol 2018;11:399-427. doi: 10.1016/ B978-0-12-801238-3.64236-8

Kam N, Perera K, Zomer E, Liew D, Ademi Z. Inclisiran as adjunct lipid-lowering therapy for patients with cardiovascular disease: A cost-effectiveness analysis. Pharmacoeconomics 2020;38:1007-20. doi: 10.1007/s40273-020-00948-w, PMID 32789593

FDA Approves Leqvio: A First-in-Class Cholesterol-Lowering Medication. 2022. Available from: fda-approves-leqvio [Last accessed on 2022 May 19].



How to Cite

VENUNGOPAL, P., K. BALAKRISHNAN, D. K. SRIRAM, and M. GEORGE. “INCLISIRAN (LEQVIO): A FIRST-IN-CLASS SMALL INTERFERING RNA THERAPEUTIC DRUG APPROVED BY FDA FOR TREATING PRIMARY HYPERCHOLESTEROLEMIA OR DYSLIPIDEMIA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 12, Dec. 2022, pp. 42-46, doi:10.22159/ajpcr.2022.v15i12.46054.



Review Article(s)